P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID

• H. Einsele,
• B. Dhakal,
• R. Potluri,
• J. Schecter,
• W. Deraedt,
• N. Lendvai,
• A. Slaughter,
• C. Lonardi,
• S. Nair,
• J. He,
• J. Voelker,
• P. Cost,
• S. Valluri,
• F. Yalniz,
• L. Pacaud,
• K. Yong

Affiliations

H. Einsele

1 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Denmark

B. Dhakal

2 Medical College of Wisconsin, Milwaukee, WI, USA

R. Potluri

3 SmartAnalyst Inc, New York, NY, USA

J. Schecter

4 Janssen R&D, Raritan, NJ, USA

W. Deraedt

5 Janssen Pharmaceutica NV, Beerse, Belgium

N. Lendvai

4 Janssen R&D, Raritan, NJ, USA

A. Slaughter

6 Cilag GmbH International, Zug, Switzerland

C. Lonardi

7 Janssen, Buenos Aires, Argentina

S. Nair

5 Janssen Pharmaceutica NV, Beerse, Belgium

J. He

8 Janssen Global Services, LLC, Raritan, NJ, USA

J. Voelker

9 Janssen Scientific Affairs, LLC, Horsham, PA, USA

P. Cost

8 Janssen Global Services, LLC, Raritan, NJ, USA

S. Valluri

8 Janssen Global Services, LLC, Raritan, NJ, USA

F. Yalniz

10 Legend Biotech USA, Piscataway, NJ, USA

L. Pacaud

10 Legend Biotech USA, Piscataway, NJ, USA

K. Yong

11 University College London Cancer Institute, London, United Kingdom